32 results on '"Masi, Gianluca"'
Search Results
2. REDISCOVER International Guidelines on the Perioperative Care of Surgical Patients With Borderline-resectable and Locally Advanced Pancreatic Cancer
3. Predictive Impact of RNF43 Mutations in Patients With Proficient Mismatch Repair/Microsatellite Stable BRAFV600E-Mutated Metastatic Colorectal Cancer Treated With Target Therapy or Chemotherapy
4. Circulating Tumor DNA as a Marker of Minimal Residual Disease After Radical Resection of Colorectal Liver Metastases
5. Techniques of parenchyma-sparing hepatectomy for the treatment of tumors involving the hepatocaval confluence: A reliable way to assure an adequate future liver remnant volume
6. First-line therapy for mCRC — the influence of primary tumour location on the therapeutic algorithm
7. OPINION: First-line chemotherapy for mCRC—a review and evidence-based algorithm
8. Tivantinib, a new option for second-line treatment of advanced hepatocellular carcinoma? The experience of Italian centers
9. Correlation between LDH levels and response to sorafenib in HCC patients: an analysis of the ITA.LI.CA database
10. Role of NRAS mutations as prognostic and predictive markers in metastatic colorectal cancer
11. Initial Therapy with FOLFOXIRI and Bevacizumab for Metastatic Colorectal Cancer
12. Adjuvant Systemic Chemotherapy After Putative Curative Resection of Colorectal Liver and Lung Metastases
13. Resectable liver metastases from colorectal cancer: where we are now and where do we go from here?
14. Outcome of Second-Line Treatment After First-Line Chemotherapy With the GONO FOLFOXIRI Regimen
15. Anti-HER agents in gastric cancer: from bench to bedside
16. Randomized Trial of Two Induction Chemotherapy Regimens in Metastatic Colorectal Cancer: An Updated Analysis
17. Refractory neuroendocrine tumor—response to liposomal doxorubicin and capecitabine
18. Pharmacokinetics, a main actor in a many-sided approach to severe 5-FU toxicity prediction
19. Optimal approach to potentially resectable liver metastases from colorectal cancer
20. Motoneuron disease after electric injury: a case report
21. EGF-receptor targeting with monoclonal antibodies in colorectal carcinomas:: rationale for a pharmacogenomic approach
22. Triplet Combination of Fluoropyrimidines, Oxaliplatin, and Irinotecan in the First-Line Treatment of Metastatic Colorectal Cancer
23. Sensitivity and specificity of a self-administered questionnaire for familial screening of adult-onset dystonia
24. Validity of Family History Data on Primary Adult-Onset Dystonia
25. Biweekly Chemotherapy With Oxaliplatin, Irinotecan, Infusional Fluorouracil, and Leucovorin: A Pilot Study in Patients With Metastatic Colorectal Cancer
26. BI-WEEKLY IRINOTECAN (CPT-11), OXALIPLATIN (LOHP), LEUCOVORIN (LV) AND 5-FLUOROURACIL (5-FU) 48 HRS. CONTINUOUS INFUSION IN ADVANCED COLORECTAL CANCER (ACRC): 673
27. Sequence Effect of Irinotecan and Fluorouracil Treatment on Pharmacokinetics and Toxicity in Chemotherapy-Naive Metastatic Colorectal Cancer Patients
28. Hypersensitivity acute reaction related to Oxaliplatin (L-OHP) infusion.
29. IRINOTECAN (CPT-11), OXALIPLATIN (LOHP), LEUCOVORIN (LV) AND 5-FLUOROURACIL (5-FU) IN METASTATIC COLORECTAL CANCER (CRC): CONCLUDED AND PLANNED STUDIES BY THE GRUPPO ONCOLOGICO NORD OVEST (G.O.N.O.).
30. Phase I-II study of gemcitabine (GEM) in combination with 24 hours continuous infusion (CI) of 5-fluorouracil (5-FU) and leucovorin (LV) in patients (pts) with advanced pancreatic carcinoma (APC).
31. Evidence of significant antitumor activity in a phase I-II study with bi-weekly irinotecan (CPT-11), oxaliplatin (LOHP), leucovorin (LV) and 5-fluorouracil (5-FU) 48 hrs continuous infusion in advanced colorectal cancer.
32. PHASE I-II STUDY OF BI-WEEKLY IRINOTECAN (CPT-11), OXALIPLATIN (LOHP), LEUCOVORIN (LV) AND 5-FLUOROURACIL (5-FU) 48 HRS CONTINUOUS INFUSION IN ADVANCED COLORECTAL CANCER.
Catalog
Books, media, physical & digital resources
Discovery Service for Jio Institute Digital Library
For full access to our library's resources, please sign in.